An improved cell-based method for determining the γ-secretase enzyme activity against both Notch and APP substrates

Journal of Neuroscience Methods

Volumn 213, Issue 1, 2013, Pages 14-21

  McKee, Timothy D ^a   Loureiro, Robyn M B ^a   Dumin, Jo Ann ^a   Zarayskiy, Vladislav ^a   Tate, Barbara ^a  

^a Satori Pharmaceuticals   (United States)

Author keywords

Secretase; A ; Alzheimer's Disease; Modulator; NICD; Notch

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AVAGACESTAT; BEGACESTAT; E 2012; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; GAMMA SECRETASE MODULATOR; JNJ 40418677; L 685 458; L 685458; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; NOTCH RECEPTOR; SEMAGACESTAT; SPI 1865; UNCLASSIFIED DRUG;

ARTICLE; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; IC 50; PREDICTION; PRIORITY JOURNAL;

ALANINE; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; AZEPINES; CELL LINE; ENZYME INHIBITORS; HUMANS; OXADIAZOLES; RECEPTORS, NOTCH; SOLID PHASE EXTRACTION; SUBSTRATE SPECIFICITY; SULFONAMIDES; THIOPHENES;

EID: 84871778196     PISSN: 01650270     EISSN: 1872678X     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2012.11.011     Document Type: Article

References (36)

1. Burton C.R., Meredith J.E., Barten D.M., Goldstein M.E., Krause C.M., Kieras C.J., et al. The amyloid-beta rise and gamma-secretase inhibitor potency depend on the level of substrate expression. J Biol Chem 2008, 283:22992-23003.
2. Chavez-Gutierrez L., Bammens L., Benilova I., Vandersteen A., Benurwar M., Borgers M., et al. The mechanism of gamma-secretase dysfunction in familial Alzheimer disease. EMBO J 2012, 31:2261-2274.
3. Ellisen L.W., Bird J., West D.C., Soreng A.L., Reynolds T.C., Smith S.D., et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991, 66:649-661.
4. Fre S., Huyghe M., Mourikis P., Robine S., Louvard D., Artavanis-Tsakonas S. Notch signals control the fate of immature progenitor cells in the intestine. Nature 2005, 435:964-968.
5. Gillman K.W., Starrett J.E., Parker M.F., Xie K., Bronson J., Marcin L., et al. Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable γ-secretase inhibitor. ACS Med Chem Lett 2010, 1:120-124.
6. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
7. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
8. Hashimoto T., Ishibashi A., Hagiwara H., Murata Y., Takenaka O., Miyagawa T. E2012: a novel gamma-secretase modulator-pharmacology part. Alzheimer's Dement 2010, 6:S242.
9. Haugabook S.J., Yager D.M., Eckman E.A., Golde T.E., Younkin S.G., Eckman C.B. High throughput screens for the identification of compounds that alter the accumulation of the Alzheimer's amyloid beta peptide (Abeta). J Neurosci Methods 2001, 108:171-179.
10. Henley D.B., May P.C., Dean R.A., Siemers E.R. Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease. Expert Opin Pharmacother 2009, 10:1657-1664.
11. Hopkins C.R. ACS chemical neuroscience molecule spotlight on begacestat (GSI-953). ACS Chem Neurosci 2012, 3:3-4.
12. Jensen J., Pedersen E.E., Galante P., Hald J., Heller R.S., Ishibashi M., et al. Control of endodermal endocrine development by Hes-1. Nat Genet 2000, 24:36-44.
13. Kreft A., Harrison B., Aschmies S., Atchison K., Casebier D., Cole D.C., et al. Discovery of a novel series of Notch-sparing gamma-secretase inhibitors. Bioorg Med Chem Lett 2008, 18:4232-4236.
14. Lanz T.A., Wood K.M., Richter K.E., Nolan C.E., Becker S.L., Pozdnyakov N., et al. Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014. J Pharmacol Exp Therap 2010, 334:269-277.
15. Liao Y.F., Wang B.J., Cheng H.T., Kuo L.H., Wolfe M.S. Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J Biol Chem 2004, 279:49523-49532.
16. Lilly E. Lilly halts development of semagacestat for Alzheimer's disease based on preliminary results of phase III clinical trials 2010, PR Newswire. http://newsroom.lilly.com/releasedetail.cfm%3Freleaseid=499794.
17. Martone R.L., Zhou H., Atchison K., Comery T., Xu J.Z., Huang X., et al. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Therap 2009, 331:598-608.
18. Mayer S.C., Kreft A.F., Harrison B., Abou-Gharbia M., Antane M., Aschmies S., et al. Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease. J Med Chem 2008, 51:7348-7351.
19. Miele L., Osborne B. Arbiter of differentiation and death: Notch signaling meets apoptosis. J Cell Physiol 1999, 181:393-409.
20. Milano J., McKay J., Dagenais C., Foster-Brown L., Pognan F., Gadient R., Jacobs R.T., Zacco A., Greenberg B., Ciaccio P.J. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 2004, 82:341-358.
21. Murphy M.P., Uljon S.N., Fraser P.E., Fauq A., Lookingbill H.A., Findlay K.A., et al. Presenilin 1 regulates pharmacologically distinct gamma-secretase activities. Implications for the role of presenilin in gamma-secretase cleavage. J Biol Chem 2000, 275:26277-26284.
22. Ohki Y., Higo T., Uemura K., Shimada N., Osawa S., Berezovska O., et al. Phenylpiperidine-type gamma-secretase modulators target the transmembrane domain 1 of presenilin 1. EMBO J 2011, 30:4815-4824.
23. Pissarnitski D. Advances in gamma-secretase modulation. Curr Opin Drug Discov Dev 2007, 10:392-402.
24. Qi-Takahara Y., Morishima-Kawashima M., Tanimura Y., Dolios G., Hirotani N., Horikoshi Y., et al. Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. J Neurosci: Off J Soc Neurosci 2005, 25:436-445.
25. Searfoss G.H., Jordan W.H., Calligaro D.O., Galbreath E.J., Schirtzinger L.M., Berridge B.R., Gao H., Higgins M.A., May P.C., Ryan T.P. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem 2003, 278:46107-46116.
26. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 1991, 6:487-498.
27. Selkoe D.J. Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 2011, 17:1060-1065.
28. Tsao P., Wei S.C., Huang M.T., Lee M.C., Chou H.C., Chen C.Y., et al. Lipopolysaccharide-induced Notch signaling activation through JNK-dependent pathway regulates inflammatory response. J Biomed Sci 2011, 15:56.
29. Van Broeck B., Chen J.M., Tréton G., Desmidt M., Hopf C., Ramsden N., et al. Chronic treatment with a novel γ-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease. Br J Pharmacol 2011, 163:375-389.
30. van Es J.H., van Gijn M.E., Riccio O., Van Den Born M., Vooijs M., Begthel H., et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005, 435:959-963.
31. Weggen S., Eriksen J.L., Das P., Sagi S.A., Wang R., Pietrzik C.U., et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001, 414:212-216.
32. Weng A.P., Nam Y., Wolfe M.S., Pear W.S., Griffin J.D., Blacklow S.C., et al. Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol 2003, 23:655-664.
33. Wolfe M.S. Gamma-secretase inhibitors and modulators for Alzheimer's disease. J Neurochem 2012, 120(Suppl. 1):89-98.
34. Wong G.T., Manfra D., Poulet F.M., Zhang Q., Josien H., Bara T., Engstrom L., Pinzon-Ortiz M., Fine J.S., Lee H.J., Zhang L., Higgins G.A., Parker E.M. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004, 297:12876-12882.
35. Xia W., McKee T., Loureiro R., Austin W., Bronk B., Creaser S., et al. Classification of γ-secretase modulators by their effect on pharmacological profiles of amyloid β peptides. AAIC 2011 2011, P2-P513.
36. Zhao G., Mao G., Tan J., Dong Y., Cui M., Kim S., et al. Identification of a new presenilin-dependent ζ-cleavage site within the transmembrane domain of amyloid precursor protein. JBC 2004, 279:50647-50650.